| Autor: |
Baratta SJ; Hospital Universitario Austral, Buenos Aires, Argentina. E-mail: sbaratta@hospitalaustral.edu.ar., Miroli A; Hospital Churruca-Visca, Buenos Aires, Argentina., Pose Cabarcos J; Sanatorio Otamendi Miroli, Buenos Aires, Argentina., Bezares RF; Hospital Teodoro álvarez, Buenos Aires, Argentina. |
| Jazyk: |
Spanish; Castilian |
| Zdroj: |
Medicina [Medicina (B Aires)] 2022; Vol. 82 (6), pp. 914-926. |
| Abstrakt: |
Advances in knowledge incorporated in the last decade have modified the treatment paradigm in most of the malignant hematological diseases. In particular, the introduction of Bruton tyrosine kinase inhibitors (BTKi) and other target drugs together with new monoclonal antibodies have become agents of choice for both chronic lymphocytic leukemia (CLL) and other peripheral "B" lymphomas such as mantle cell lymphoma (MCL). The results of efficacy against genotoxic therapy are so successful that the end of chemoimmunotherapy, especially for CLL, is already a postulate recognized by the main research groups. On the other hand, the new drugs modified the profile of adverse events, which forced the development of new subspecialties such as cardio-oncology, which currently constitutes a bastion for the rational management of these patients. This review aims to highlight the current state of knowledge on these pathologies, pharmacological principles together with new adverse events of iBTK and the invaluable contribution of cardiology for correct management of these patients. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
